Viracta Therapeutics/VIRX

$0.86

-2.73%
-
1D1W1MYTD1YMAX

About Viracta Therapeutics

Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Ticker

VIRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Rothera

Employees

40

Headquarters

Cardiff by the sea, United States

VIRX Metrics

BasicAdvanced
$33.64M
Market cap
-
P/E ratio
-$1.32
EPS
0.94
Beta
-
Dividend rate
$33.64M
0.94099
$2.38
$0.43
115.66K
1.432
137.966
-141.21%
-66.88%
-149.04%
-97.91%
2.603
1.837
-1.48%

What the Analysts think about VIRX

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
713.95% upside
High $13.00
Low $4.00
$0.86
Current price
$7.00
Average price target

VIRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-13.7M
8.73%
Profit margin
0%
-

VIRX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 12.9%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.32
-$0.32
-$0.33
-$0.35
-
Expected
-$0.31
-$0.29
-$0.31
-$0.31
-$0.35
Surprise
2.4%
10.34%
8.2%
12.9%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Viracta Therapeutics stock?

Viracta Therapeutics (VIRX) has a market cap of $33.64M as of April 23, 2024.

What is the P/E ratio for Viracta Therapeutics stock?

The price to earnings (P/E) ratio for Viracta Therapeutics (VIRX) stock is 0 as of April 23, 2024.

Does Viracta Therapeutics stock pay dividends?

No, Viracta Therapeutics (VIRX) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Viracta Therapeutics dividend payment date?

Viracta Therapeutics (VIRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Viracta Therapeutics?

Viracta Therapeutics (VIRX) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Viracta Therapeutics stock price target?

The target price for Viracta Therapeutics (VIRX) stock is $7, which is 713.95% above the current price of $0.86. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Viracta Therapeutics stock

Buy or sell Viracta Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing